Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · IEX Real-Time Price · USD
33.04
-0.92 (-2.71%)
At close: Mar 28, 2024, 4:00 PM
33.90
+0.86 (2.60%)
After-hours: Mar 28, 2024, 7:50 PM EDT

Beam Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Cash & Equivalents
444.61245.52572.74177.0150.55147.941.93
Short-Term Investments
753.98845.37405.65137.554.6300
Cash & Cash Equivalents
1,1991,091978.39314.51105.18147.941.93
Cash Growth
9.87%11.50%211.08%199.02%-28.90%7561.11%-
Receivables
003000000
Other Current Assets
12.452.01-5.39-6.19-10.640.340.11
Total Current Assets
1,2111,0931,273308.3294.54148.282.04
Property, Plant & Equipment
237.81234.13186.98125.3743.2516.940.34
Other Long-Term Assets
10.8714.6914.4717.9818.311.790.03
Total Long-Term Assets
248.67248.82201.45143.3661.5618.740.37
Total Assets
1,4601,3421,474451.68156.1167.012.4
Accounts Payable
1.629.037.476.317.857.350.73
Deferred Revenue
178.59338.15348.570.42000
Current Debt
12.7810.389.836.345.6413.750
Other Current Liabilities
12.58-133.97-152.4489.2715.654.495.84
Total Current Liabilities
205.57223.6213.44102.3429.1425.596.57
Long-Term Debt
159.91168.63137.82101.3125.600
Other Long-Term Liabilities
112.91216.02296.462.470.427.40.02
Total Long-Term Liabilities
272.82384.65434.28103.7826.027.40.02
Total Liabilities
478.39608.24647.72206.1255.1532.986.59
Total Debt
172.69179.01147.64107.6431.2413.750
Debt Growth
-3.53%21.24%37.16%244.59%127.19%--
Retained Earnings
-1,189.89-1,057.36-768.27-397.64-203.04-124.72-9.46
Comprehensive Income
0.6-2.43-0.05-0.010.0200
Shareholders' Equity
981.33733.47826.74245.56-201.1-117.41-9.44
Net Cash / Debt
1,026911.88830.75206.8773.94134.191.93
Net Cash / Debt Growth
12.50%9.77%301.59%179.77%-44.90%6849.04%-
Net Cash Per Share
13.3013.0212.934.4311.4146.377.47
Working Capital
1,005869.31,060205.9865.41122.69-4.53
Book Value Per Share
12.7210.4812.875.25-31.04-40.57-36.51
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).